AbbVie Inc. (NYSE:ABBV) was the recipient of some unusual options trading on Monday. Stock traders acquired 278 put options on the company. This is an increase of approximately 121% compared to the average daily volume of 126 put options.

A number of analysts have recently weighed in on ABBV shares. Vetr raised AbbVie from a “hold” rating to a “buy” rating and set a $74.86 price objective for the company in a research note on Thursday, July 6th. Jefferies Group LLC reissued a “buy” rating and set a $94.00 price objective (up previously from $92.00) on shares of AbbVie in a research note on Monday, July 17th. Societe Generale raised AbbVie from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. BidaskClub lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $85.00 price objective on shares of AbbVie in a research note on Thursday, August 3rd. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. AbbVie has a consensus rating of “Buy” and a consensus price target of $82.38.

In other news, Chairman Richard A. Gonzalez sold 193,131 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the completion of the sale, the chairman now owns 469,623 shares of the company’s stock, valued at $33,343,233. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Richard A. Gonzalez sold 87,899 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $71.02, for a total value of $6,242,586.98. Following the sale, the chairman now directly owns 342,353 shares of the company’s stock, valued at approximately $24,313,910.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 373,191 shares of company stock valued at $26,598,305. Insiders own 0.23% of the company’s stock.

Several hedge funds have recently modified their holdings of the business. Bogart Wealth LLC lifted its holdings in shares of AbbVie by 36.2% in the 2nd quarter. Bogart Wealth LLC now owns 24,439 shares of the company’s stock worth $1,772,000 after buying an additional 6,491 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in shares of AbbVie in the 2nd quarter worth $1,581,000. Frontier Investment Mgmt Co. lifted its holdings in shares of AbbVie by 34.8% in the 2nd quarter. Frontier Investment Mgmt Co. now owns 9,979 shares of the company’s stock worth $724,000 after buying an additional 2,574 shares during the period. W. E. Donoghue & Co. LLC purchased a new stake in shares of AbbVie in the 2nd quarter worth $16,696,000. Finally, Intl Fcstone Inc. lifted its holdings in shares of AbbVie by 188.4% in the 2nd quarter. Intl Fcstone Inc. now owns 30,430 shares of the company’s stock worth $2,206,000 after buying an additional 19,878 shares during the period. Institutional investors and hedge funds own 68.25% of the company’s stock.

AbbVie (NYSE:ABBV) opened at 87.41 on Thursday. AbbVie has a 12 month low of $55.06 and a 12 month high of $89.69. The stock has a market cap of $139.34 billion, a price-to-earnings ratio of 21.50 and a beta of 1.48. The firm’s 50-day moving average price is $75.76 and its 200 day moving average price is $69.87.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The business had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. During the same period in the prior year, the business earned $1.26 EPS. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. On average, analysts anticipate that AbbVie will post $5.52 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a $0.64 dividend. This represents a $2.56 annualized dividend and a dividend yield of 2.93%. The ex-dividend date is Thursday, October 12th. AbbVie’s dividend payout ratio is 62.90%.

WARNING: “Traders Buy Large Volume of Put Options on AbbVie (ABBV)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/traders-buy-large-volume-of-put-options-on-abbvie-abbv/1576773.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.